Eisai Inc.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a global research-based pharmaceutical company. Guided by its human health care (hhc) philosophy, Eisai Inc. is dedicated to the discovery, development, manufacturing, and marketing of pharmaceutical products. The company's mission is to deliver life-changing therapies and health-related solutions to help people live healthier and more fulfilling lives. Its U.S. headquarters are located in Nutley, New Jersey.

Eisai Inc. focuses its research and commercial efforts primarily on two core therapeutic areas: Neurology and Oncology, addressing diseases with high unmet medical needs, such as Alzheimer's disease and various cancers. Key products available in the U.S. market include LEQEMBI® (lecanemab-irmb) for Alzheimer's disease, DAYVIGO® (lemborexant) for insomnia, LENVIMA® (lenvatinib) for certain cancers, Banzel (rufinamide) for seizures, and Halaven (eribulin mesylate) for metastatic breast cancer. The company also offers patient support programs like Eisai Cares.

In recent years, Eisai Inc. relocated its U.S. headquarters to Nutley, New Jersey, in March 2022, consolidating its operations and fostering innovation. A significant development was the U.S. FDA approval of LEQEMBI® (lecanemab) for Alzheimer's disease in January 2023. The company continues to present data on real-world treatment with Lecanemab and engage in clinical trials for various conditions. Tatsuyuki Yasuno serves as the President of Eisai Inc. & Americas Region.